Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Metabolism and Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2133/DMPK.DMPK-12-RG-084PMID 23358260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial

  2012cited by this paper
• Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

  2009cited by this paper
• American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

  2006cited by this paper
• ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

  2006cited by this paper
• Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.

  2005cited by this paper
• Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5‐hydroxytryptamine type 3 antagonists

  2005cited by this paper
• Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression.

  2005cited by this paper
• シスプラチンによる遅発性悪心•嘔吐に対する薬物療法の検討：システマティック•レビュー

  2004cited by this paper
• A variant 2677A allele of the MDR1 gene affects fexofenadine disposition

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• [Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review].

  2004cited by this paper
• Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics

  2003cited by this paper
• ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation.

  2003cited by this paper
• Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects

  2002cited by this paper
• Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.

  2002cited by this paper
• Contribution of P‐glycoprotein to efflux of ramosetron, a 5‐HT3 receptor antagonist, across the blood‐brain barrier

  2002cited by this paper
• Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects.

  2002cited by this paper
• Significant Genetic Linkage of MDR1 Polymorphisms at Positions 3435 and 2677: Functional Relevance to Pharmacokinetics of Digoxin

  2002cited by this paper
• The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol

  2002cited by this paper
• Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.

  2001cited by this paper
• MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects

  2001cited by this paper
• Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999cited by this paper
• Pharmacological insights from P-glycoprotein knockout mice.

  1998cited by this paper
• Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters.

  1997cited by this paper
• An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting.

  1997cited by this paper
• Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

  1997cited by this paper
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

  1996cited by this paper
• Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.

  1995cited by this paper
• Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.

  1995cited by this paper
• Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.

  1994cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper
• Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.

  1992cited by this paper
• Physiology of nausea and vomiting.

  1992cited by this paper
• Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

  1991cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper

• Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: HTR3A, HTR3B, TACR1

  2025cites this paper
• Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study

  2024cites this paper
• Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV

  2021cites this paper
• Metagenomics and chemotherapy‐induced nausea: A roadmap for future research

  2021cites this paper
• An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and Vomiting

  2021cites this paper
• Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy

  2020cites this paper
• Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.

  2020cites this paper
• Drug–drug–gene interactions and adverse drug reactions

  2019cites this paper
• Clinical Significance

  2019cites this paper
• A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.

  2018cites this paper
• Neuroanesthesiology Update

  2018cites this paper
• A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research

  2018cites this paper
• Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors

  2018cites this paper
• Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting

  2017cites this paper
• Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline‐based Chemotherapy

  2017cites this paper
• Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

  2017cites this paper
• Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms

  2017cites this paper
• The Physiology and Pharmacology of Nausea and Vomiting Induced by Anticancer Chemotherapy in Humans

  2016cites this paper
• Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

  2016cites this paper
• Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting

  2016cites this paper
• Improved Anti‐Emetic Efficacy of 5‐HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter

  2015cites this paper
• Pharmacogenetics of chemotherapy-induced nausea and vomiting.

  2015cites this paper
• The Antiemetic Efficacy of Aprepitant in Patients with Advanced Non-small-cell Lung Cancer Who Are Treated with Pemetrexed and Carboplatin

  2015cites this paper
• Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?

  2014cites this paper
• X-ray analysis of the effect of the 5-HT3 receptor antagonist granisetron on gastrointestinal motility in rats repeatedly treated with the antitumoral drug cisplatin

  2014cites this paper